Skip to main content

EcoR1 Capital, LLC

13F filer · CIK 0001587114
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$2.06BU.S. long equity reported on 13F
Positions309 new · 7 closed
Net flow last quarter-$967MBuys minus sells
Top 10 positions weight86.3%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202630 positions
ZYMEZymeworks Inc.$600M29.19%32.17%Not reportedQ1 2020
ANABAnaptysbio, Inc$532M25.86%27.08%-33.3%Q4 2019
AKTSAktis Oncology, Inc.$155M7.56%9.03%Not reportedQ1 2026
CGONCG Oncology, Inc.$106M5.16%1.69%+35.6%Q4 2025
ETONEton Pharmaceuticals, Inc.$78.6M3.82%7.68%Not reportedQ3 2024
CRSPCRISPR Therapeutics AG$75.8M3.68%1.44%Not reportedQ3 2018
ORICOric Pharmaceuticals, Inc.$72.9M3.54%6.49%Not reportedQ2 2020
TRAXFirst Tracks Biotherapeutics, Inc.$63.9M3.11%8.97%NewQ2 2026
LKFTLakefront Biotherapeutics NV$50M2.43%2.53%Not reportedQ4 2015
NGNENeurogene Inc.$40M1.94%8.03%Not reportedQ4 2023
STOKStoke Therapeutics, Inc.$24M1.17%1.18%+635.0%Q1 2026
FULCFulcrum Therapeutics, Inc.$24M1.17%8.59%Not reportedQ2 2020
LEGNLegend Biotech Corp$23.1M1.12%0.22%Not reportedQ4 2021
BBOTBridgeBio Oncology Therapeutics, Inc.$21.5M1.05%3.52%Not reportedQ3 2025
MBXMBX Biosciences, Inc.$21.4M1.04%0.81%-50.0%Q3 2024
ZBIOZenas BioPharma, Inc.$20M0.97%1.25%Not reportedQ4 2025
ATRAAtara Biotherapeutics, Inc.$17.8M0.87%16.44%+1458.3%Q4 2014
RLAYRelay Therapeutics, Inc.$13.1M0.63%0.32%-63.4%Q3 2020
AURAAura Biosciences, Inc.$11.8M0.58%1.61%NewQ2 2026
ODTXOdyssey Therapeutics, Inc.$10.4M0.51%1.16%NewQ2 2026
EIKNEikon Therapeutics, Inc.$9.56M0.46%1.35%Not reportedQ1 2026
PHVSPharvaris N.V.$8.13M0.40%0.36%Not reportedQ4 2023
ZURAZura Bio Ltd$6.96M0.34%1.24%Not reportedQ1 2026
PHATPhathom Pharmaceuticals, Inc.$6.78M0.33%0.78%Not reportedQ2 2023
NRIXNurix Therapeutics, Inc.$6.55M0.32%0.26%Not reportedQ3 2020
ERASErasca, Inc.$6.05M0.29%0.11%-63.3%Q3 2021
ELOXEloxx Pharmaceuticals, Inc.$5.55M0.27%9.91%NewQ2 2026
AARDAardvark Therapeutics, Inc.$2.28M0.11%1.81%NewQ2 2026
HLXCHelix Acquisition Corp. III$2.13M0.10%Not reportedNot reportedQ1 2026
MREOMereo BioPharma Group plc$318K0.02%0.13%-92.5%Q4 2025
Q1 2026Reported May 15, 202628 positions
ZYMEZymeworks Inc.$575M24.41%31.42%Not reportedQ1 2020
ANABAnaptysbio, Inc$437M18.55%27.14%Not reportedQ4 2019
JAZZJazz Pharmaceuticals plc$323M13.69%2.77%Not reportedQ2 2023
CNTACentessa Pharmaceuticals PLC$238M10.11%3.88%+92.6%Q2 2021
CRNXCrinetics Pharmaceuticals, Inc.$156M6.61%4.07%Not reportedQ1 2020
AKTSAktis Oncology, Inc.$86.3M3.66%9.03%NewQ1 2026
ORICOric Pharmaceuticals, Inc.$85.2M3.62%6.50%Not reportedQ2 2020
CGONCG Oncology, Inc.$74.6M3.17%1.25%+42.8%Q4 2025
CRSPCRISPR Therapeutics AG$66.1M2.80%1.44%Not reportedQ3 2018
ETONEton Pharmaceuticals, Inc.$53.6M2.27%7.94%+7.0%Q3 2024
LKFTLakefront Biotherapeutics NV$50M2.12%2.53%Not reportedQ4 2015
XNCRXencor Inc$26.3M1.12%2.95%-32.9%Q2 2016
NGNENeurogene Inc.$25.6M1.09%8.14%Not reportedQ4 2023
BBOTBridgeBio Oncology Therapeutics, Inc.$25.3M1.07%3.53%Not reportedQ3 2025
MBXMBX Biosciences, Inc.$23.2M0.98%1.63%-63.4%Q3 2024
RLAYRelay Therapeutics, Inc.$19M0.80%1.01%Not reportedQ3 2020
ZBIOZenas BioPharma, Inc.$15.4M0.66%1.27%Not reportedQ4 2025
ERASErasca, Inc.$14.6M0.62%0.29%Not reportedQ3 2021
EIKNEikon Therapeutics, Inc.$7.75M0.33%1.35%NewQ1 2026
REPLReplimune Group, Inc.$7.65M0.32%1.21%Not reportedQ2 2024
ZURAZura Bio Ltd$7.02M0.30%1.24%NewQ1 2026
PHATPhathom Pharmaceuticals, Inc.$6.94M0.29%0.79%Not reportedQ2 2023
MREOMereo BioPharma Group plc$4.41M0.19%1.68%+70.2%Q4 2025
STOKStoke Therapeutics, Inc.$3.26M0.14%0.16%NewQ1 2026
PRLDPrelude Therapeutics Inc$3.24M0.14%1.50%Not reportedQ2 2023
IBIOiBio, Inc.$3.01M0.13%4.58%-29.0%Q4 2025
HLXCHelix Acquisition Corp. III$2.03M0.09%Not reportedNewQ1 2026
ATRAAtara Biotherapeutics, Inc.$471K0.02%1.17%-82.6%Q4 2014
Q4 2025Reported Feb 17, 202627 positions
ZYMEZymeworks Inc.$605M27.44%30.78%Not reportedQ1 2020
ANABAnaptysbio, Inc$382M17.33%28.12%Not reportedQ4 2019
JAZZJazz Pharmaceuticals plc$290M13.16%2.78%Not reportedQ2 2023
CRNXCrinetics Pharmaceuticals, Inc.$200M9.06%4.49%Not reportedQ1 2020
CNTACentessa Pharmaceuticals PLC$77.9M3.53%2.09%+466.4%Q2 2021
CRSPCRISPR Therapeutics AG$72.9M3.31%1.45%Not reportedQ3 2018
MBXMBX Biosciences, Inc.$67M3.04%4.73%Not reportedQ3 2024
IMNMImmunome Inc.$61.3M2.78%2.52%-30.0%Q4 2023
ORICOric Pharmaceuticals, Inc.$55M2.50%6.83%Not reportedQ2 2020
LKFTLakefront Biotherapeutics NV$54.5M2.47%2.53%Not reportedQ4 2015
XNCRXencor Inc$49.8M2.26%4.52%-47.1%Q2 2016
BBOTBridgeBio Oncology Therapeutics, Inc.$35.3M1.60%3.53%Not reportedQ3 2025
ETONEton Pharmaceuticals, Inc.$34.3M1.56%7.51%Not reportedQ3 2024
CGONCG Oncology, Inc.$32.1M1.45%0.96%NewQ4 2025
ZBIOZenas BioPharma, Inc.$28.7M1.30%1.45%NewQ4 2025
NGNENeurogene Inc.$26.2M1.19%8.21%Not reportedQ4 2023
GPCRStructure Therapeutics Inc.$23.3M1.06%0.16%NewQ4 2025
PCVXVaxcyte, Inc.$20.8M0.94%0.34%Not reportedQ4 2021
AQSTAquestive Therapeutics, Inc.$17M0.77%2.15%Not reportedQ3 2025
VYGRVoyager Therapeutics, Inc.$15.7M0.71%6.78%+497.2%Q3 2021
ATRAAtara Biotherapeutics, Inc.$10.4M0.47%7.83%Not reportedQ4 2014
MNKDMannkind Corp$9.41M0.43%0.54%NewQ4 2025
NUVBNuvation Bio Inc.$8.63M0.39%0.28%Not reportedQ1 2021
EOLSEvolus, Inc.$4.49M0.20%1.04%Not reportedQ4 2019
IBIOiBio, Inc.$4.3M0.20%7.41%NewQ4 2025
MREOMereo BioPharma Group plc$3.27M0.15%0.99%NewQ4 2025
CAMPCamp4 Therapeutics Corp$1.99M0.09%0.63%NewQ4 2025
Q3 2025Reported Nov 14, 202529 positions
ZYMEZymeworks Inc.$392M18.83%30.57%Not reportedQ1 2020
ANABAnaptysbio, Inc$241M11.58%28.58%Not reportedQ4 2019
QUREuniQure N.V.$233M11.17%6.42%Not reportedQ4 2024
JAZZJazz Pharmaceuticals plc$225M10.79%2.81%Not reportedQ2 2023
CRNXCrinetics Pharmaceuticals, Inc.$179M8.57%4.54%Not reportedQ1 2020
CRSPCRISPR Therapeutics AG$90M4.32%1.48%Not reportedQ3 2018
TNGXTango Therapeutics, Inc.$89.3M4.29%9.53%Not reportedQ3 2021
ORICOric Pharmaceuticals, Inc.$80.7M3.87%6.92%+315.8%Q2 2020
APLSApellis Pharmaceuticals, Inc.$78M3.74%2.73%-71.0%Q4 2017
XNCRXencor Inc$72.1M3.46%8.61%Not reportedQ2 2016
LKFTLakefront Biotherapeutics NV$57.7M2.77%2.53%+60.8%Q4 2015
IMNMImmunome Inc.$47.8M2.29%4.45%Not reportedQ4 2023
ETONEton Pharmaceuticals, Inc.$44.1M2.12%7.57%Not reportedQ3 2024
MBXMBX Biosciences, Inc.$37.2M1.78%4.75%+84.7%Q3 2024
MDGLMadrigal Pharmaceuticals, Inc.$34.4M1.65%0.33%Not reportedQ4 2017
RNAMAvidity Biosciences, Inc.$33.3M1.60%0.52%+53.0%Q2 2020
BBOTBridgeBio Oncology Therapeutics, Inc.$32.7M1.57%3.56%NewQ3 2025
NGNENeurogene Inc.$22M1.06%8.60%Not reportedQ4 2023
ALKSAlkermes plc.$15M0.72%0.30%Not reportedQ2 2025
AQSTAquestive Therapeutics, Inc.$14.7M0.70%2.16%NewQ3 2025
MTSRMetsera, Inc.$14.2M0.68%0.26%Not reportedQ1 2025
CNTACentessa Pharmaceuticals PLC$13.3M0.64%0.41%Not reportedQ2 2021
PRMEPrime Medicine, Inc.$8.55M0.41%0.86%Not reportedQ4 2022
ATRAAtara Biotherapeutics, Inc.$8.21M0.39%7.95%Not reportedQ4 2014
KURAKura Oncology, Inc.$7.72M0.37%1.00%-79.2%Q4 2015
PEPGPepGen Inc.$3.7M0.18%2.44%NewQ3 2025
NUVBNuvation Bio Inc.$3.56M0.17%0.29%Not reportedQ1 2021
VYGRVoyager Therapeutics, Inc.$3.13M0.15%1.21%-82.9%Q3 2021
CMPSCOMPASS Pathways plc$1.52M0.07%0.28%NewQ3 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.